Related Experiment Video
Updated: Mar 16, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
Hypolipidemic effects of HVC1 in a high cholesterol diet‑induced rat model of hyperlipidemia
Chae-Yun Kim1, Kyung-Sook Chung1, Se-Yun Cheon1
1Department of Pharmacology, College of Oriental Medicine, Sangji University, Wonju, Gangwon‑do 220702, Republic of Korea.
Insights
HVC1, a novel herbal formulation, effectively lowered cholesterol and reduced body weight in rats with diet-induced hyperlipidemia. This suggests HVC1
Area of Science:
- Pharmacology
- Natural Products
- Cardiovascular Research
Background:
- Hyperlipidemia is a significant risk factor for cardiovascular diseases.
- Novel therapeutic agents are needed to manage hyperlipidemia effectively.
- Herbal formulations offer potential for developing new hypolipidemic treatments.
Purpose of the Study:
- To investigate the hypolipidemic effects of HVC1, a novel four-herb formulation.
- To evaluate HVC1's efficacy in a rat model of high cholesterol diet-induced hyperlipidemia.
Main Methods:
- Rats were fed a high cholesterol diet for 8 weeks to induce hyperlipidemia.
- HVC1 was administered orally at doses of 10, 50, or 250 mg/kg.
- Serum lipid profiles, body weight, liver/aorta lipid accumulation, and gene/protein expression were analyzed.
Main Results:
- HVC1 significantly reduced body weight and improved serum lipid profiles (total cholesterol, LDL-C, HDL-C).
- HVC1 decreased lipid accumulation in the liver and aorta.
- HVC1 modulated the expression of key genes (PPAR-γ, HMGCR, LDLR) and proteins (AMPK) involved in lipid metabolism.
Conclusions:
- HVC1 demonstrates potent hypolipidemic effects in a preclinical model.
- The findings support HVC1's potential as a therapeutic agent for hyperlipidemia.
- Further evaluation of HVC1 for hyperlipidemia treatment is warranted.
Abstract:
HVC1, a novel formation containing four herbs, was developed and its hypolipidemic effects in rats with high cholesterol diet (HCD)‑induced hyperlipidemia were investigated. The rats were given a HCD for 8 weeks. The HVC1‑treated groups were orally administered HVC1 at doses of 10, 50 or 250 mg/kg, respectively, and the simvastatin group was treated at a dose of 10 mg/kg. The normal diet and HCD control groups were administered with physiological saline. Oral administration of HVC1 (10, 50 or 250 mg/kg) significantly reduced the body weight of rats with hyperlipidemia and regulated the total cholesterol, low‑density lipoprotein cholesterol and high‑density lipoprotein cholesterol levels in the serum. In addition, tissue analysis revealed that lipid accumulation in the liver and aorta was reduced by HVC1 administration. Furthermore, HVC1 significantly reduced the mRNA expression of peroxisome proliferator‑activated receptor‑γ, 3‑hydroxy‑3‑methylglutaryl‑CoA reductase and low‑density lipoprotein receptor, as well as the protein level of 5' adenosine monophosphate‑activated protein kinase in the liver. The results clearly demonstrate that HVC1 has a potent hypolipidemic effect, and suggest that HVC1 should be evaluated as a potential treatment for hyperlipidemia.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipid Digestion

